drugset
Drugs / ThermoDox
last change Oct 2021 re-read 3 minutes ago

ThermoDox

Developed for
metastasis from malignant tumor of colon
Investigated by
Imunon

Trials 1

today NCT01464593 · Ph 2
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01464593 Sep 2011 → May 2013 metastasis from malignant tumor of colon Imunon Terminated No outcome recorded

Press releases naming this drug 141 releases

DateIssuerRelease
2021-10-11 Imunon Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews imunon.com ↗
2021-07-01 Imunon Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer imunon.com ↗
2021-06-23 Imunon Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox® imunon.com ↗
2020-06-25 Imunon Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer imunon.com ↗
2020-04-15 Imunon Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer imunon.com ↗
2020-02-04 Imunon Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference imunon.com ↗
2019-12-18 Imunon Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia imunon.com ↗
2019-11-14 Imunon Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia imunon.com ↗
2019-11-04 Imunon Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer imunon.com ↗
2019-08-27 Imunon Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics imunon.com ↗
2019-08-13 Imunon Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology imunon.com ↗
2019-08-05 Imunon Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer imunon.com ↗
Show all 141 releases opens the full record — a long page

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ThermoDox “ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.” NCT01464593 ↗
Route Intravenous “administered intravenously (IV)” NCT01464593 ↗